254 related articles for article (PubMed ID: 27986463)
1. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.
Muluhngwi P; Krishna A; Vittitow SL; Napier JT; Richardson KM; Ellis M; Mott JL; Klinge CM
Cancer Lett; 2017 Mar; 388():230-238. PubMed ID: 27986463
[TBL] [Abstract][Full Text] [Related]
2. The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells.
Muluhngwi P; Alizadeh-Rad N; Vittitow SL; Kalbfleisch TS; Klinge CM
Sci Rep; 2017 Jul; 7(1):5205. PubMed ID: 28701793
[TBL] [Abstract][Full Text] [Related]
3. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
Petri BJ; Piell KM; South Whitt GC; Wilt AE; Poulton CC; Lehman NL; Clem BF; Nystoriak MA; Wysoczynski M; Klinge CM
Cancer Lett; 2021 Oct; 518():152-168. PubMed ID: 34273466
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells.
Petri BJ; Piell KM; Wilt AE; Howser AD; Winkler L; Whitworth MR; Valdes BL; Lehman NL; Clem BF; Klinge CM
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37650685
[TBL] [Abstract][Full Text] [Related]
6. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription.
Klinge CM; Riggs KA; Wickramasinghe NS; Emberts CG; McConda DB; Barry PN; Magnusen JE
Mol Cell Endocrinol; 2010 Jul; 323(2):268-76. PubMed ID: 20302909
[TBL] [Abstract][Full Text] [Related]
8. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
[TBL] [Abstract][Full Text] [Related]
9. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X
Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173
[TBL] [Abstract][Full Text] [Related]
10. Regulation of miR-29b-1/a transcription and identification of target mRNAs in CHO-K1 cells.
Muluhngwi P; Richardson K; Napier J; Rouchka EC; Mott JL; Klinge CM
Mol Cell Endocrinol; 2017 Mar; 444():38-47. PubMed ID: 28137615
[TBL] [Abstract][Full Text] [Related]
11. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
12. Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells.
Muluhngwi P; Klinge CM
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298743
[TBL] [Abstract][Full Text] [Related]
13. HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.
Klinge CM; Piell KM; Tooley CS; Rouchka EC
Sci Rep; 2019 Jul; 9(1):9430. PubMed ID: 31263129
[TBL] [Abstract][Full Text] [Related]
14. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
15. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
[TBL] [Abstract][Full Text] [Related]
16. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
17. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.
Selever J; Gu G; Lewis MT; Beyer A; Herynk MH; Covington KR; Tsimelzon A; Dontu G; Provost P; Di Pietro A; Boumendjel A; Albain K; Miele L; Weiss H; Barone I; Ando S; Fuqua SA
Clin Cancer Res; 2011 Oct; 17(20):6510-21. PubMed ID: 21878538
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy.
Liu ZR; Song Y; Wan LH; Zhang YY; Zhou LM
Life Sci; 2016 Mar; 149():104-13. PubMed ID: 26896688
[TBL] [Abstract][Full Text] [Related]
19. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
Han X; Li Q; Liu C; Wang C; Li Y
J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
[TBL] [Abstract][Full Text] [Related]
20. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
Li XN; Liu AH; Tang X; Ren Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
